Natural history of excessive daytime sleepiness: a population-based 5-year longitudinal study.


Journal

Sleep
ISSN: 1550-9109
Titre abrégé: Sleep
Pays: United States
ID NLM: 7809084

Informations de publication

Date de publication:
12 03 2020
Historique:
received: 20 05 2019
revised: 05 09 2019
pubmed: 15 10 2019
medline: 15 4 2021
entrez: 15 10 2019
Statut: ppublish

Résumé

To document the rates of persistent, remitted, and intermittent excessive daytime sleepiness (EDS) in a longitudinal 5-year community study of adults and to assess how changes in risk factors over time can predict improvement of daytime sleepiness (DS). Participants were recruited in 2007-2008 as part of a population-based epidemiological study implemented in Canada. They completed postal assessments at baseline and at each yearly follow-up. An Epworth Sleepiness Scale total score >10 indicated clinically significant EDS; a 4-point reduction between two consecutive evaluations defined DS improvement. Socio-demographic, lifestyle, health characteristics, and sleep-related measures (e.g. insomnia symptoms, sleep duration, sleep medication) were self-reported at each time point. Cox proportional-hazard models were used to predict EDS and DS remissions over 5 years. Among the 2167 participants, 33% (n = 714) met criteria for EDS at baseline, of whom 33% had persistent EDS, 44% intermittent EDS, and 23% remitted EDS over the follow-up. Furthermore, 61.4% of 2167 initial participants had stable DS, 27.1% sustained DS improvement and 8.5% transient improvement over the follow-up. The main predictors of EDS remission or DS improvement were normal weight, taking less hypnotics, having hypertension, increased nighttime sleep duration, and decreased insomnia, and depressive symptoms. EDS waxes and wanes over time with frequent periods of remission and is influenced by behavioral characteristics and changes in psychological, metabolic, and nighttime sleep patterns. Targeting these predictors in future interventions is crucial to reduce DS in the general adult population.

Identifiants

pubmed: 31608404
pii: 5586812
doi: 10.1093/sleep/zsz249
pmc: PMC7066486
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Sleep Research Society 2019. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.

Références

Sleep. 2012 Sep 01;35(9):1201-7
pubmed: 22942498
Lancet Neurol. 2013 Nov;12(11):1068-75
pubmed: 24107292
PLoS One. 2013;8(2):e56048
pubmed: 23457496
Sleep Med Rev. 2014 Aug;18(4):321-31
pubmed: 24135493
Arch Gen Psychiatry. 2012 Jan;69(1):71-9
pubmed: 22213791
Arch Intern Med. 2002 Jan 28;162(2):201-8
pubmed: 11802754
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Ann Neurol. 2013 Jun;73(6):785-94
pubmed: 23846792
Biol Psychiatry. 1996 Mar 15;39(6):411-8
pubmed: 8679786
Neurology. 2000 Mar 14;54(5):1166-75
pubmed: 10720292
Am J Geriatr Psychiatry. 2015 Aug;23(8):818-28
pubmed: 25499672
Chest. 1987 Apr;91(4):540-6
pubmed: 3829746
Sleep Med. 2010 Dec;11(10):973-9
pubmed: 20961809
Sleep Med. 2009 Feb;10(2):182-8
pubmed: 18684665
Semin Neurol. 2005 Mar;25(1):106-16
pubmed: 15798943
J Clin Endocrinol Metab. 2005 Aug;90(8):4510-5
pubmed: 15941867
Stroke. 2009 Apr;40(4):1219-24
pubmed: 19246707
Arch Intern Med. 2009 Mar 9;169(5):447-53
pubmed: 19273774
Sleep Med Rev. 2008 Apr;12(2):129-41
pubmed: 18342261
BMJ. 2002 May 11;324(7346):1125
pubmed: 12003884
Sleep. 2015 Mar 01;38(3):351-60
pubmed: 25581913
J Clin Psychiatry. 2005 Apr;66(4):521-9
pubmed: 15816796
Sci Rep. 2017 May 2;7(1):1372
pubmed: 28465612
Sleep. 2015 Dec 01;38(12):1995-2003
pubmed: 26237774
JAMA. 1989 Sep 15;262(11):1479-84
pubmed: 2769898
J Sleep Res. 2007 Dec;16(4):364-71
pubmed: 18036081
CNS Drugs. 2004;18(5):297-328
pubmed: 15089115
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246

Auteurs

I Jaussent (I)

INSERM, University Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France.

C M Morin (CM)

Department of Psychology, Université Laval, Quebec City, Quebec, Canada.

H Ivers (H)

Department of Psychology, Université Laval, Quebec City, Quebec, Canada.

Y Dauvilliers (Y)

INSERM, University Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France.
CHU Montpellier, Service de Neurologie, Unité des Troubles du Sommeil, Hôpital Gui-de-Chauliac, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH